Back to top

Tandem Diabetes resumed with a Neutral at UBS

UBS resumed coverage of Tandem Diabetes (TNDM) with a Neutral rating with a price target of $18, down from $22, as part of a broader note on U.S. M...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tandem Diabetes Care, Inc. (TNDM)